Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.49 |
| ▸ | BRD4 | O60885 | 2/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.48 |
| ▸ | MAP1LC3B | Q9GZQ8 | 5/20 | 0.48 |
| ▸ | STAT3 | P40763 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23766130 | 0.94 | CRBN (0.52) | CRBNBRD4HDAC3HDAC1IKZF3 | |
| SCHEMBL23766126 | 0.88 | MAP1LC3B (0.49) | CRBNBRD4HDAC3HDAC1IKZF3 | |
| SCHEMBL24068343 | 0.88 | CRBN (0.48) | CRBNBRD4IKZF3MAP1LC3BSTAT3 | |
| SCHEMBL23765742 | 0.86 | CRBN (0.51) | CRBNBRD4HDAC3HDAC1IKZF3 | |
| SCHEMBL25032251 | 0.84 | STAT3 (0.52) | CRBNBRD4HDAC3HDAC1IKZF3 | |
| SCHEMBL19438825 | 0.84 | CRBN (0.55) | CRBNBRD4HDAC3HDAC1IKZF3 | |
| SCHEMBL19438857 | 0.84 | CRBN (0.55) | CRBNBRD4HDAC3HDAC1IKZF3 | |
| SCHEMBL30577345 | 0.84 | CRBN (0.55) | CRBNBRD4HDAC3HDAC1IKZF3 | |
| SCHEMBL20913661 | 0.84 | CRBN (0.55) | CRBNBRD4HDAC3HDAC1IKZF3 | |
| SCHEMBL25756262 | 0.83 | STAT3 (0.51) | CRBNBRD4HDAC3HDAC1IKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210369853-A1 | TARGETED PROTEASE DEGRADATION PLATFORM | EUBULUS BIOTHERAPEUTICS INC. (CN) | 2021-12-02 | — | — | US | disclosed |
| EP-3865152-A1 | TARGETED PROTEASE DEGRADATION PLATFORM | Eubulus Biotherapeutics Inc. (CN) | 2021-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210369853-A1 | TARGETED PROTEASE DEGRADATION PLATFORM | PSMB1, MDM2, XIAP | CRBN 284/4885BRD4 1676/4885HDAC3 1968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.